Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lung Diseases 2 Lung Non-Squamous Non-Small Cell Carcinoma 1 Lung Neoplasms 1 Carcinoma 1

Interventions

pembrolizumab 25 Cisplatin 23 Carboplatin 18 Magnetic Resonance Spectroscopy 16 Paclitaxel 15 Specimen Handling 14 Pemetrexed 11 durvalumab 9 Radiotherapy, Intensity-Modulated 8 Platinum 8 1,2-diaminocyclohexaneplatinum II citrate 8 Nivolumab 7 Radiation 6 Docetaxel 6 Cetuximab 6 Biopsy 6 osimertinib 5 cemiplimab 5 Taxes 5 Radiotherapy 5 Ipilimumab 5 Cyclophosphamide 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 poly ICLC 4 cabozantinib 4 atezolizumab 4 Oxaliplatin 4 Gemcitabine 4 Fluorouracil 4 Bevacizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × zipalertinib × 1 year × Clear all

NCT05967689 2026-05-28

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡